OTSUKA
OTSKFDrugs in Pipeline
157
Phase 3 Programs
101
Upcoming Catalysts
10
Next Catalyst
This month
Market Overview
Stock performance and key metrics
10 upcoming, 0 past
OPC-61815 injection
Congestive Heart Failure
ASC-01
Major Depressive Disorder
0.3% OPA-15406
Atopic Dermatitis
Lithium
Bipolar Disorder Mania
0.3% OPA-15406 Ointment
Atopic Dermatitis (AD)
OPA-15406
Atopic Dermatitis
OPC-61815
Congestive Heart Failure
CDP870 200mg
Rheumatoid Arthritis
OPC-41061
Cirrhosis
SEP-363856
Schizophrenia
Certolizumab Pegol
Rheumatoid Arthritis
Brexpiprazole (OPC-34712)
Schizophrenia
SPM 962
Idiopathic Restless Legs Syndrome
Rebamipide 1%
Keratoconjunctivitis Sicca
Centanafadine
Major Depressive Disorder
Tolvaptan Suspension
Autosomal Recessive Polycystic Kidney (ARPKD)
SEP-363856 50mg
Schizophrenia
SEP363856
Schizophrenia
JNT-517
Phenylketonuria (PKU)
Brexpiprazole
Major Depressive Disorder
Ropinirole
Parkinson's Disease
SEP-363856 75mg
Schizophrenia
Meptin swinghaler
Asthma
Aripiprazole depot 300 or 400 mg
Schizophrenia
Aripiprazole (Fixed dose)
Major Depressive Disorder
Quetiapine extended release
Schizophrenia
Aripiprazole
Schizophrenia
Busulfan
Multiple Myeloma
Aripiprazole (BMS-337039)
Dementia, Alzheimer Type
Aripiprazole+ ADT
Major Depressive Disorder
Olanzapine or Quetiapine or Risperidone
Schizophrenia
Tolvaptan (OPC-41061)
Autosomal Recessive Polycystic Kidney Disease (ARPKD)
Antidepressant + Aripiprazole
Major Depressive Disorder
OPC-34712
Schizophrenia
Vadadustat
Anemia
Aripiprazole Low (2 mg/day)
Schizophrenia
Cilostazol
Vasospastic Angina
EB-1020 (Centanafadine) 164.4 mg
Attention Deficit Hyperactivity Disorder (ADHD)
Aripiprazole and aripiprazole once-monthly
Schizophrenia
JNT-517 Tablet
Phenylketonuria (PKU)
AVP-786
Agitation in Patients With Dementia of the Alzheimer's Type
CDP870
Rheumatoid Arthritis
Aripiprazole Oral Solution
Autistic Disorder
Aripiprazole (Abilifyยฎ) IM Depot Injection
Schizophrenia
Hyalein Mini Ophthalmic solution
Dry Eye Syndromes
Aripiprazole IM Depot
Schizophrenia
OPC-41061(Tolvaptan)
Cardiac Edema
Aripiprazole tablet
Schizophrenia
OPC-14597 (Aripiprazole)
Major Depressive Disorder
TEV-48125
Migraine
Aripiprazole depot
Schizophrenia
Procaterol, Salbultamol
Moderate Acute Asthma
Brexpiprazole, OPC-34712
Agitation Associated With
High Dose Melphalan
Myeloma
Delamanid (DLM)
Tuberculosis, MDR
Aripiprazole tablet, 10 mg
Schizophrenia
OPC-12759 Ophthalmic suspension
Dry Eye Syndromes
OPC-41061 ๏ผTolvaptan)
Cardiac Edema
OPC-6535
Crohn's Disease
OPC-34712 + ADT
Depressive Disorder
OPC-34712FUM/ Brexpiprazole fumarate
Acute Schizophrenia
Asacolยฎ
Ulcerative Colitis
AVP-786-18
Agitation in Participants With Dementia of the Alzheimer's Type
BPaQM
Pulmonary Tuberculosis
Centanafadine SR
Attention Deficit Disorder
Seroquel XR
Depressive Disorder
Sibeprenlimab 400 mg
Immunoglobulin A Nephropathy
180mg of ETC-1002(bempedoic acid)
Hyper-low-density Lipoprotein (LDL) Cholesterolemia
Subcutaneous azacitidine
Myelodysplastic Syndromes
Cilostazol 200mg/day Oral
Cerebral Infarction
Latanoprost ophthalmic solution
Glaucoma
OPC-34712 [Brexpiprazole] High Dose
Acute Schizophrenia
Meptinยฎ Swinghaler
Asthma
Escitalopram
Depressive Disorder
OPC-6535 Tablets (drug)
Ulcerative Colitis
MCT-SR
Acute Gastritis
Abilify 2, 5, 10, 15mg (Tablet)
Depression, Bipolar
Rebamipide and Omeprazole
Gastric Ulcer
Rebamipide
Keratoconjunctivitis Sicca
OPC-1085EL ophthalmic solution
Glaucoma
Centanafadine XR
Attention-deficit/Hyperactivity Disorder
EB-1020 (Centanafadine) low dose
Attention-Deficit Hyperactivity Disorder(ADHD)
Tolvaptan
Congestive Heart Failure
OPC-1085EL
Open Angle Glaucoma or Ocular Hypertension
Nalmefene hydrochloride
Alcohol Dependence
Misoprostol
Rheumatoid Arthritis
CDP870 400mg
Rheumatoid Arthritis
centanafadine capsule
Attention Deficit/Hyperactivity Disorder
Probucol
Hyperlipidemia
OPC-12759
Dry Eye
1% OPA-15406 ointment
Atopic Dermatitis
Haloperidol
Bipolar Disorder
Brexpiprazole +ADT
Depressive Disorder
EB-1020 (Centanafadine) 328.8 mg
Attention Deficit Hyperactivity Disorder (ADHD)
EB-1020 (Centanafadine) high dose
Attention-Deficit Hyperactivity Disorder(ADHD)
Delamanid + OBR
Multidrug-resistant Tuberculosis
ADT
Major Depressive Disorder
Centanafadine Hydrochloride
Attention-Deficit/Hyperactivity Disorder
1% OPA-15406
Atopic Dermatitis
Tolvaptan Oral Tablet
Syndrome of Inappropriate Antidiuretic Hormone Secretion
Each subject will subcutaneously self-administer TEV 48125 at 225 mg/1.5 mL (150 mg/mL) once monthly for a total of 2 doses.
Migraine
IRL757
PARKINSON DISEASE (Disorder)
OCV-501
Acute Myeloid Leukemia
Delamanid + Bedaquiline + OPC-167832 10 mg
Pulmonary TB
Sodium hyaluronate ophthalmic solution
Keratoconjunctival Epithelial Disorder
OPB-31121
Hepatocellular Carcinoma
OPC-64005
Adult Attention Deficit Hyperactivity Disorder
OPC-249
Pain Due to Osteoporosis
IV busulfan
Multiple Myeloma
Optimized Background Regimen (OBR)
Tuberculosis, Pulmonary
OPC-41061 7.5mg
Cirrhosis
13C-uracil
Dyspeptic Subjects
OPC-64005 20 mg , Once-daily
Major Depressive Disorder
Probucol 250mg/day
Diabetic Nephropathy
tetomilast (OPC-6535)
Chronic Obstructive Pulmonary Disease
0.5% OPC-12759
Dry Eye Syndromes
Delamanid
Tuberculosis, Multidrug-Resistant
10 mg OPC-167832
Pulmonary TB
CTN SR
Attention Deficit Disorder With Hyperactivity
Cilostazol, Probucol
Peripheral Artery Disease
IV Decitabine
Myelodysplastic Syndromes
1% OPC-12759 ophthalmic suspension
Dry Eye Syndromes
Calcium (13C)Carbonate
Gastric Acid-related Diseases
Gastric acid inhibitors
Gastroesophageal Reflux Disease
Tolvaptan MR
Autosomal Dominant Polycystic Kidney Disease
Tolvaptan IR
Autosomal Dominant Polycystic Kidney Disease
Sibeprenlimab
IgA Nephropathy
OPC-18
Hepatocellular Carcinoma
OPS-2071 tablet
Bacterial Enteritis
Delamanid Pediatric Formulation (DPF)
Multidrug Resistant Tuberculosis
OPC-67683
Pulmonary Tuberculosis
2% Rebamipide liquid
Head and Neck Cancer
OPS-2071
Irritable Bowel Syndrome of Diarrhea Type (IBS-D)
Vesnarinone
Sarcoma, Kaposi
IV Busulfan, Cyclophosphamide and Etoposide (BuCyE Regimen)
Lymphoma
OPC 131461 10mg group
Cardiac Edema (CHF)
AVP-786-28
Neurobehavioral Disinhibition
Low Dose-VIS649
Immunoglobulin A Nephropathy
Rexulti
Borderline Personality Disorder
120mg of ETC-1002(bempedoic acid)
Hypercholesterolemia
AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination)
Depressive Disorder, Treatment-Resistant
Ponatinib 30mg OD
Chronic Myeloid Leukemia
OPDC-34712
Attention Deficit Hyperactivity Disorder
OPC-415
Multiple Myeloma (MM)
JNT-517 Suspension
Phenylketonuria
rabbit anti-thymocyte globulin (ATG)
Chronic Myeloproliferative Disorders
Aripiprazole + IEM (Ingestible Event Marker)
Schizophrenia
Busulfan, Fludarabine, Cytoxan
Lymphoma
busulfan, melphalan and fludarabine
Multiple Myeloma
Bedaquiline
Tuberculosis, Multidrug-Resistant
PB
Autosomal Dominant Polycystic Kidney Disease
High-dose chemotherapy
Non-Hodgkin's Lymphoma
Flu/Bu4 conditioning regimen
Hematological Malignancies
Aripiprazole tablet, 5-30mg/day, oral, 6 weeks
Schizophrenia
Linezolid 600 mg
Tuberculosis, Multidrug-Resistant
Optimized multidrug background regimen (OBR) for children with MDR-TB
Tuberculosis
Clofarabine/Busulfan x 4
Acute Myeloblastic Leukemia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
OPC-61815 injection | Phase 3 | Congestive Heart Failure | - | - |
ASC-01 | Phase 3 | Major Depressive Disorder | - | - |
0.3% OPA-15406 | Phase 3 | Atopic Dermatitis | - | - |
Lithium | Phase 3 | Bipolar Disorder Mania | - | - |
0.3% OPA-15406 Ointment | Phase 3 | Atopic Dermatitis (AD) | - | - |
OPA-15406 | Phase 3 | Atopic Dermatitis | - | - |
OPC-61815 | Phase 3 | Congestive Heart Failure | - | - |
CDP870 200mg | Phase 3 | Rheumatoid Arthritis | - | - |
OPC-41061 | Phase 3 | Cirrhosis | - | - |
SEP-363856 | Phase 3 | Schizophrenia | - | - |
Certolizumab Pegol | Phase 3 | Rheumatoid Arthritis | - | - |
Brexpiprazole (OPC-34712) | Phase 3 | Schizophrenia | - | - |
SPM 962 | Phase 3 | Idiopathic Restless Legs Syndrome | - | - |
Rebamipide 1% | Phase 3 | Keratoconjunctivitis Sicca | - | - |
Centanafadine | Phase 3 | Major Depressive Disorder | - | - |
Tolvaptan Suspension | Phase 3 | Autosomal Recessive Polycystic Kidney (ARPKD) | - | - |
SEP-363856 50mg | Phase 3 | Schizophrenia | - | - |
SEP363856 | Phase 3 | Schizophrenia | - | - |
JNT-517 | Phase 3 | Phenylketonuria (PKU) | - | - |
Brexpiprazole | Phase 3 | Major Depressive Disorder | - | - |
Ropinirole | Phase 3 | Parkinson's Disease | - | - |
SEP-363856 75mg | Phase 3 | Schizophrenia | - | - |
Meptin swinghaler | Phase 3 | Asthma | - | - |
Aripiprazole depot 300 or 400 mg | Phase 3 | Schizophrenia | - | - |
Aripiprazole (Fixed dose) | Phase 3 | Major Depressive Disorder | - | - |
Quetiapine extended release | Phase 3 | Schizophrenia | - | - |
Aripiprazole | Phase 3 | Schizophrenia | - | - |
Busulfan | Phase 3 | Multiple Myeloma | - | - |
Aripiprazole (BMS-337039) | Phase 3 | Dementia, Alzheimer Type | - | - |
Aripiprazole+ ADT | Phase 3 | Major Depressive Disorder | - | - |
Olanzapine or Quetiapine or Risperidone | Phase 3 | Schizophrenia | - | - |
Tolvaptan (OPC-41061) | Phase 3 | Autosomal Recessive Polycystic Kidney Disease (ARPKD) | - | - |
Antidepressant + Aripiprazole | Phase 3 | Major Depressive Disorder | - | - |
OPC-34712 | Phase 3 | Schizophrenia | - | - |
Vadadustat | Phase 3 | Anemia | - | - |
Aripiprazole Low (2 mg/day) | Phase 3 | Schizophrenia | - | - |
Cilostazol | Phase 3 | Vasospastic Angina | - | - |
EB-1020 (Centanafadine) 164.4 mg | Phase 3 | Attention Deficit Hyperactivity Disorder (ADHD) | - | - |
Aripiprazole and aripiprazole once-monthly | Phase 3 | Schizophrenia | - | - |
JNT-517 Tablet | Phase 3 | Phenylketonuria (PKU) | - | - |
AVP-786 | Phase 3 | Agitation in Patients With Dementia of the Alzheimer's Type | - | - |
CDP870 | Phase 3 | Rheumatoid Arthritis | - | - |
Aripiprazole Oral Solution | Phase 3 | Autistic Disorder | - | - |
Aripiprazole (Abilifyยฎ) IM Depot Injection | Phase 3 | Schizophrenia | - | - |
Hyalein Mini Ophthalmic solution | Phase 3 | Dry Eye Syndromes | - | - |
Aripiprazole IM Depot | Phase 3 | Schizophrenia | - | - |
OPC-41061(Tolvaptan) | Phase 3 | Cardiac Edema | - | - |
Aripiprazole tablet | Phase 3 | Schizophrenia | - | - |
OPC-14597 (Aripiprazole) | Phase 3 | Major Depressive Disorder | - | - |
TEV-48125 | Phase 3 | Migraine | - | - |
Aripiprazole depot | Phase 3 | Schizophrenia | - | - |
Procaterol, Salbultamol | Phase 3 | Moderate Acute Asthma | - | - |
Brexpiprazole, OPC-34712 | Phase 3 | Agitation Associated With | - | - |
High Dose Melphalan | Phase 3 | Myeloma | - | - |
Delamanid (DLM) | Phase 3 | Tuberculosis, MDR | - | - |
Aripiprazole tablet, 10 mg | Phase 3 | Schizophrenia | - | - |
OPC-12759 Ophthalmic suspension | Phase 3 | Dry Eye Syndromes | - | - |
OPC-41061 ๏ผTolvaptan) | Phase 3 | Cardiac Edema | - | - |
OPC-6535 | Phase 3 | Crohn's Disease | - | - |
OPC-34712 + ADT | Phase 3 | Depressive Disorder | - | - |
OPC-34712FUM/ Brexpiprazole fumarate | Phase 3 | Acute Schizophrenia | - | - |
Asacolยฎ | Phase 3 | Ulcerative Colitis | - | - |
AVP-786-18 | Phase 3 | Agitation in Participants With Dementia of the Alzheimer's Type | - | - |
BPaQM | Phase 3 | Pulmonary Tuberculosis | - | - |
Centanafadine SR | Phase 3 | Attention Deficit Disorder | - | - |
Seroquel XR | Phase 3 | Depressive Disorder | - | - |
Sibeprenlimab 400 mg | Phase 3 | Immunoglobulin A Nephropathy | - | - |
180mg of ETC-1002(bempedoic acid) | Phase 3 | Hyper-low-density Lipoprotein (LDL) Cholesterolemia | - | - |
Subcutaneous azacitidine | Phase 3 | Myelodysplastic Syndromes | - | - |
Cilostazol 200mg/day Oral | Phase 3 | Cerebral Infarction | - | - |
Latanoprost ophthalmic solution | Phase 3 | Glaucoma | - | - |
OPC-34712 [Brexpiprazole] High Dose | Phase 3 | Acute Schizophrenia | - | - |
Meptinยฎ Swinghaler | Phase 3 | Asthma | - | - |
Escitalopram | Phase 3 | Depressive Disorder | - | - |
OPC-6535 Tablets (drug) | Phase 3 | Ulcerative Colitis | - | - |
MCT-SR | Phase 3 | Acute Gastritis | - | - |
Abilify 2, 5, 10, 15mg (Tablet) | Phase 3 | Depression, Bipolar | - | - |
Rebamipide and Omeprazole | Phase 3 | Gastric Ulcer | - | - |
Rebamipide | Phase 3 | Keratoconjunctivitis Sicca | - | - |
OPC-1085EL ophthalmic solution | Phase 3 | Glaucoma | - | - |
Centanafadine XR | Phase 3 | Attention-deficit/Hyperactivity Disorder | - | - |
EB-1020 (Centanafadine) low dose | Phase 3 | Attention-Deficit Hyperactivity Disorder(ADHD) | - | - |
Tolvaptan | Phase 3 | Congestive Heart Failure | - | - |
OPC-1085EL | Phase 3 | Open Angle Glaucoma or Ocular Hypertension | - | - |
Nalmefene hydrochloride | Phase 3 | Alcohol Dependence | - | - |
Misoprostol | Phase 3 | Rheumatoid Arthritis | - | - |
CDP870 400mg | Phase 3 | Rheumatoid Arthritis | - | - |
centanafadine capsule | Phase 3 | Attention Deficit/Hyperactivity Disorder | - | - |
Probucol | Phase 3 | Hyperlipidemia | - | - |
OPC-12759 | Phase 3 | Dry Eye | - | - |
1% OPA-15406 ointment | Phase 3 | Atopic Dermatitis | - | - |
Haloperidol | Phase 3 | Bipolar Disorder | - | - |
Brexpiprazole +ADT | Phase 3 | Depressive Disorder | - | - |
EB-1020 (Centanafadine) 328.8 mg | Phase 3 | Attention Deficit Hyperactivity Disorder (ADHD) | - | - |
EB-1020 (Centanafadine) high dose | Phase 3 | Attention-Deficit Hyperactivity Disorder(ADHD) | - | - |
Delamanid + OBR | Phase 3 | Multidrug-resistant Tuberculosis | - | - |
ADT | Phase 3 | Major Depressive Disorder | - | - |
Centanafadine Hydrochloride | Phase 3 | Attention-Deficit/Hyperactivity Disorder | - | - |
1% OPA-15406 | Phase 3 | Atopic Dermatitis | - | - |
Tolvaptan Oral Tablet | Phase 3 | Syndrome of Inappropriate Antidiuretic Hormone Secretion | - | - |
Each subject will subcutaneously self-administer TEV 48125 at 225 mg/1.5 mL (150 mg/mL) once monthly for a total of 2 doses. | Phase 3 | Migraine | - | - |
IRL757 | Phase 2 | PARKINSON DISEASE (Disorder) | - | - |
OCV-501 | Phase 2 | Acute Myeloid Leukemia | - | - |
Delamanid + Bedaquiline + OPC-167832 10 mg | Phase 2 | Pulmonary TB | - | - |
Sodium hyaluronate ophthalmic solution | Phase 2 | Keratoconjunctival Epithelial Disorder | - | - |
OPB-31121 | Phase 2 | Hepatocellular Carcinoma | - | - |
OPC-64005 | Phase 2 | Adult Attention Deficit Hyperactivity Disorder | - | - |
OPC-249 | Phase 2 | Pain Due to Osteoporosis | - | - |
IV busulfan | Phase 2 | Multiple Myeloma | - | - |
Optimized Background Regimen (OBR) | Phase 2 | Tuberculosis, Pulmonary | - | - |
OPC-41061 7.5mg | Phase 2 | Cirrhosis | - | - |
13C-uracil | Phase 2 | Dyspeptic Subjects | - | - |
OPC-64005 20 mg , Once-daily | Phase 2 | Major Depressive Disorder | - | - |
Probucol 250mg/day | Phase 2 | Diabetic Nephropathy | - | - |
tetomilast (OPC-6535) | Phase 2 | Chronic Obstructive Pulmonary Disease | - | - |
0.5% OPC-12759 | Phase 2 | Dry Eye Syndromes | - | - |
Delamanid | Phase 2 | Tuberculosis, Multidrug-Resistant | - | - |
10 mg OPC-167832 | Phase 2 | Pulmonary TB | - | - |
CTN SR | Phase 2 | Attention Deficit Disorder With Hyperactivity | - | - |
Cilostazol, Probucol | Phase 2 | Peripheral Artery Disease | - | - |
IV Decitabine | Phase 2 | Myelodysplastic Syndromes | - | - |
1% OPC-12759 ophthalmic suspension | Phase 2 | Dry Eye Syndromes | - | - |
Calcium (13C)Carbonate | Phase 2 | Gastric Acid-related Diseases | - | - |
Gastric acid inhibitors | Phase 2 | Gastroesophageal Reflux Disease | - | - |
Tolvaptan MR | Phase 2 | Autosomal Dominant Polycystic Kidney Disease | - | - |
Tolvaptan IR | Phase 2 | Autosomal Dominant Polycystic Kidney Disease | - | - |
Sibeprenlimab | Phase 2 | IgA Nephropathy | - | - |
OPC-18 | Phase 2 | Hepatocellular Carcinoma | - | - |
OPS-2071 tablet | Phase 2 | Bacterial Enteritis | - | - |
Delamanid Pediatric Formulation (DPF) | Phase 2 | Multidrug Resistant Tuberculosis | - | - |
OPC-67683 | Phase 2 | Pulmonary Tuberculosis | - | - |
2% Rebamipide liquid | Phase 2 | Head and Neck Cancer | - | - |
OPS-2071 | Phase 2 | Irritable Bowel Syndrome of Diarrhea Type (IBS-D) | - | - |
Vesnarinone | Phase 2 | Sarcoma, Kaposi | - | - |
IV Busulfan, Cyclophosphamide and Etoposide (BuCyE Regimen) | Phase 2 | Lymphoma | - | - |
OPC 131461 10mg group | Phase 2 | Cardiac Edema (CHF) | - | - |
AVP-786-28 | Phase 2 | Neurobehavioral Disinhibition | - | - |
Low Dose-VIS649 | Phase 2 | Immunoglobulin A Nephropathy | - | - |
Rexulti | Phase 2 | Borderline Personality Disorder | - | - |
120mg of ETC-1002(bempedoic acid) | Phase 2 | Hypercholesterolemia | - | - |
AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination) | Phase 2 | Depressive Disorder, Treatment-Resistant | - | - |
Ponatinib 30mg OD | Phase 2 | Chronic Myeloid Leukemia | - | - |
OPDC-34712 | Phase 2 | Attention Deficit Hyperactivity Disorder | - | - |
OPC-415 | Phase 2 | Multiple Myeloma (MM) | - | - |
JNT-517 Suspension | Phase 2 | Phenylketonuria | - | - |
rabbit anti-thymocyte globulin (ATG) | Phase 2 | Chronic Myeloproliferative Disorders | - | - |
Aripiprazole + IEM (Ingestible Event Marker) | Phase 2 | Schizophrenia | - | - |
Busulfan, Fludarabine, Cytoxan | Phase 2 | Lymphoma | - | - |
busulfan, melphalan and fludarabine | Phase 2 | Multiple Myeloma | - | - |
Bedaquiline | Phase 2 | Tuberculosis, Multidrug-Resistant | - | - |
PB | Phase 2 | Autosomal Dominant Polycystic Kidney Disease | - | - |
High-dose chemotherapy | Phase 2 | Non-Hodgkin's Lymphoma | - | - |
Flu/Bu4 conditioning regimen | Phase 2 | Hematological Malignancies | - | - |
Aripiprazole tablet, 5-30mg/day, oral, 6 weeks | Phase 2 | Schizophrenia | - | - |
Linezolid 600 mg | Phase 2 | Tuberculosis, Multidrug-Resistant | - | - |
Optimized multidrug background regimen (OBR) for children with MDR-TB | Phase 2 | Tuberculosis | - | - |
Clofarabine/Busulfan x 4 | Phase 2 | Acute Myeloblastic Leukemia | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown โ the signals behind the verdict
Frequently asked questions
What is in OTSUKA's drug pipeline?โ
CatalystAlert tracks 157 drug candidates in OTSUKA's (OTSKF) pipeline across Phase 3, Phase 2. Its lead program is OPC-61815 injection (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is OTSUKA's next FDA catalyst?โ
OTSUKA's (OTSKF) next tracked catalyst is a Phase 3 expected October 20, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track OTSKF biotech catalysts?โ
Add OTSKF to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow OTSUKA's live catalyst calendar, drug pipeline and clinical-trial timeline on this page โ sourced from ClinicalTrials.gov, FDA and SEC filings.